Physician profile
David M Werle
NPI 1740451434
$1,763.35
in general payments reported to CMS, 2019-2025
28 companies · $484 in 2025
The $484 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $74.28 · 2021: $68.89 · 2022: $190 · 2023: $392 · 2024: $269 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Education: $13.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.71 |
| Education | $13.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $267.80 | 2019-2024 | Myrbetriq |
| Sumitomo Pharma America, INC. | $213.90 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $200.84 | 2019-2025 | |
| Neotract INC. | $93.16 | 2019-2020 | |
| Tolmar, INC. | $88.64 | 2023 | |
| Teleflex LLC | $79.19 | 2023-2025 | Urolift, Barrigel |
| Janssen Biotech, INC. | $78.54 | 2019-2025 | Erleada |
| Endo Pharmaceuticals INC. | $71.87 | 2019-2023 | Aveed, Xiaflex |
| Medtronic, INC. | $69.90 | 2023-2025 | Interstim |
| Laborie Medical Technologies Corp. | $56.16 | 2023-2025 | |
| Olympus America INC. | $53.84 | 2025 | Itind System |
| Merck Sharp & Dohme LLC | $51.19 | 2022 | |
| Endo USA, INC. | $49.14 | 2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $47.04 | 2022-2023 | Jelmyto |
| Coloplast Corp | $42.07 | 2022-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verity Pharmaceuticals INC. | $37.12 | 2025 | Trelstar |
| Procept Biorobotics Corporation | $33.48 | 2024 | Aquabeam System |
| Abc Home Medical Supply, INC. | $30.50 | 2025 | |
| Abbvie INC. | $29.95 | 2019-2023 | Lupron Depot |
| Myriad Genetic Laboratories, INC. | $24.91 | 2025 | Prolaris |
| Urovant Sciences INC | $24.10 | 2022 | |
| Convatec INC. | $23.05 | 2024 | |
| Dendreon Pharmaceuticals LLC | $21.32 | 2020 | |
| Halozyme INC | $19.01 | 2023 | |
| Accord Healthcare, INC. | $17.17 | 2025 | |
| Ambu INC. | $13.26 | 2024 | |
| Ferring Pharmaceuticals INC. | $13.19 | 2024 | Adstiladrin |
| Boston Scientific Corporation | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Werle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.